0222 GMT - China Resources Pharmaceutical could grow faster than peer Sinopharm, driven by the former's traditional Chinese medicine growth likely outpacing its medical distribution business, says Morningstar's Yurou Zheng in a note. Both companies are likely to be hindered by industry developments such as prices being squeezed by tight public spending budgets and competition from e-commerce companies, he says. "We don't expect either to be able to add higher value-added medicines to their distribution business that quickly to shore up profitability," he adds. Morningstar maintains its fair-value estimates on Sinopharm and CR Pharma at HK$24.60 and HK$5.80, respectively. Sinopharm last traded at HK$19.42; CR Pharma was last at HK$5.13. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

August 26, 2025 22:22 ET (02:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.